Abstract P1-09-16: A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer and non-mutated BRCA
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p1-09-16
Abstract: Background: Poly (ADP-ribose) inhibitors (PARPi) are effective in patients (pts) with germline BRCA 1/2 and PALB2 mutations but have been largely ineffective as monotherpy in others. PARP interacts with, and is recruited to, DNA damage… read more here.
Keywords: cancer; phase study; astx727 plus; hormone resistant ... See more keywords